Galson Backed Initial Plan B Denial In Fear His Job Was In Jeopardy – Jenkins
Executive Summary
Center for Drug Evaluation & Research Director Steven Galson initially signed off on the "not approvable" letter for Barr's emergency contraceptive Plan B OTC switch in fear that he would lose his job, according to testimony by senior CDER officials
You may also be interested in...
Plan B Decision May Offer FDA Best Political Protection Available
Assuming that sexually charged products such as Teva’s emergency contraceptive remain subject to political decision-making, the explicit heavy hand of the HHS secretary in the OTC switch ruling may be the best approach for FDA and the Rx industry, especially considering the alternatives.
FDA’s Florence Houn Joins Celgene Regulatory Affairs Department
Celgene has tapped FDA's Florence Houn as VP-regulatory policy and strategy at a time when the company is working to comply with the Risk Evaluation and Mitigation Strategies provisions of the FDA Amendments Act
FDA’s Florence Houn Joins Celgene Regulatory Affairs Department
Celgene has tapped FDA's Florence Houn as VP-regulatory policy and strategy at a time when the company is working to comply with the Risk Evaluation and Mitigation Strategies provisions of the FDA Amendments Act